Subcutaneous injection of interferon gamma therapy could be useful for anti–IFN-γ autoantibody associated disseminated nontuberculous mycobacterial infection

2020 ◽  
Author(s):  
Masanori Harada ◽  
Kazuki Furuhashi ◽  
Masato Karayama ◽  
Yuzo Suzuki ◽  
Hironao Hozumi ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Subcutaneous Injection ◽  
Mycobacterial Infection ◽  
Nontuberculous Mycobacterial Infection ◽  
Ifn Γ

Treatment of Refractory Disseminated Nontuberculous Mycobacterial Infection With Interferon Gamma: A Preliminary Report

1994 ◽  
Vol 330 (19) ◽  
pp. 1348-1355 ◽  
Author(s):  
Steven M. Holland ◽  
Eli M. Eisenstein ◽  
Douglas B. Kuhns ◽  
Maria L. Turner ◽  
Thomas A. Fleisher ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Preliminary Report ◽  
Mycobacterial Infection ◽  
Nontuberculous Mycobacterial Infection

scholarly journals Factors associated with acquired Anti IFN- γ autoantibody in patients with nontuberculous mycobacterial infection

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0176342 ◽  
Author(s):  
Pakpoom Phoompoung ◽  
Nasikarn Ankasekwinai ◽  
Manop Pithukpakorn ◽  
Suporn Foongladda ◽  
Pinklow Umrod ◽  
...  
Keyword(s):  
Mycobacterial Infection ◽  
Factors Associated ◽  
Nontuberculous Mycobacterial Infection ◽  
Ifn Γ

scholarly journals Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection

Blood ◽  
2012 ◽  
Vol 119 (17) ◽  
pp. 3933-3939 ◽  
Author(s):  
Sarah K. Browne ◽  
Rifat Zaman ◽  
Elizabeth P. Sampaio ◽  
Kamonwan Jutivorakool ◽  
Lindsey B. Rosen ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Nontuberculous Mycobacteria ◽  
Mycobacterial Infection ◽  
First Year ◽  
Intracellular Pathogens ◽  
Refractory Disease ◽  
Disease Remission ◽  
Nontuberculous Mycobacterial Infection ◽  
Ifn Γ ◽  
Anti Cd20

Abstract Patients with anti–IFN-γ autoantibodies have impaired IFN-γ signaling, leading to severe disseminated infections with intracellular pathogens, especially nontuberculous mycobacteria. Disease may be severe and progressive, despite aggressive treatment. To address the underlying pathogenic IFN-γ autoantibodies we used the therapeutic monoclonal rituximab (anti-CD20) to target patient B cells. All subjects received between 8 and 12 doses of rituximab within the first year to maintain disease remission. Subsequent doses were given for relapsed infection. We report 4 patients with refractory disease treated with rituximab who had clinical and laboratory evidence of therapeutic response as determined by clearance of infection, resolution of inflammation, reduction of anti–IFN-γ autoantibody levels, and improved IFN-γ signaling.

Sign in / Sign up

Export Citation Format

Share Document